Leaving the study early · Adolescents with psychosis
It is very uncertain whether COMPUTER‐ASSISTED COGNITIVE REMEDIATION PROGRAMME (CACR) changes leaving the study early: For any reason compared with COMPUTER GAMES (CG, all short‐term) (very low certainty).
1 finding from 1 review
Global functioning: Average endpoint VABS Score (high score = good) · Adolescents with psychosis
1 finding from 1 review
Adverse events: Clinically important effect · Adolescents with psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital admissions · Adolescents with psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · Adolescents with psychosis
It is very uncertain whether COGNITIVE REMEDIATION THERAPY (CRG) + TREATMENT‐AS‐USUAL (TAU) changes leaving the study early: For any reason compared with TAU (all short‐term) (very low certainty).
1 finding from 1 review
Global state: Average endpoint score CGAS (high score = good) · Adolescents with psychosis
1 finding from 1 review
Mental state · Adolescents with psychosis
1 finding from 1 review
Global state: relapse (rehospitalised) · schizophrenia or related disorders
1 finding from 1 review
Anxiety (adverse effect, post‐intervention) · schizophrenia or related disorders
1 finding from 1 review
Functioning: clinically important change · schizophrenia or related disorders
1 finding from 1 review
Mental state · schizophrenia or related disorders
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · people with both severe mental illness and substance misuse
1 finding from 1 review
Subjective well‐being · people with both severe mental illness and substance misuse
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Craving · people with both severe mental illness and substance misuse
1 finding from 1 review
Adverse effects: Parkinsonism ‐ average endpoint score (SAS, high = worse) · people with both severe mental illness and substance misuse
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes leaving study early: any reason compared with OLANZAPINE ‒ short‐ and long‐term data (very low certainty).
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
RISPERIDONE showed no clear difference in leaving the study early: 1. any reason, long term (>12 months) compared with QUETIAPINE ‒ short‐ and long‐term data (low certainty).
1 finding from 1 review
Substance use: improvement ‒ (at least 20% reduction in use, TLFB scale) · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes substance use: improvement ‒ (at least 20% reduction in use, TLFB… compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Subjective well‐being · people with both severe mental illness and substance misuse
1 finding from 1 review
Craving · people with both severe mental illness and substance misuse
1 finding from 1 review